Why Has Mizuho Given Eagle Pharma (NASDAQ:EGRX) a $112.0 Price Target
In a comprehensive report revealed to clients on Wednesday morning, stock analysts at Mizuho launched coverage for Eagle Pharma (NASDAQ:EGRX) shares. The firm has decided to set a Buy rating along with a $112.0, adding 11.77% to the target.
The stock closed the day at $100.21 during the previous session. It is down 76.30% since May 6, 2015 and is uptrending. It has outperformed by 77.10% the S&P500.
Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to reports earnings on December, 16. They expect $-0.54 earnings per share, up 16.92% or $0.11 from last year’s $-0.65 per share. After $-0.53 actual earnings per share reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 1.89% negative EPS growth.
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $1.56 billion. The Firm focused on developing and commercializing injectable products. It currently has negative earnings. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products.
According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.” Get a free copy of the Zacks research report on Eagle Pharmaceuticals Inc (EGRX).